July 30 (Reuters) - Regeneron (REGN.O) on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped by strong demand for its eczema drug Dupixent and a high-dose version of its eye drug Eylea.

7 月 30 日（路透社）——再生元制药（REGN.O）周四公布的第二季度营收和利润均超出华尔街预期，这得益于其湿疹药物 Dupixent 和眼药 Eylea 高剂量版本的强劲需求。

Shares rose nearly 5% before the bell.

盘前股价上涨近 5%。

Here are the details:

具体细节如下：

Global net sales of Dupixent, recorded by partner Sanofi (SASY.PA) , increased 38% to about $6 billion, beating estimates of $5.34 billion, according to LSEG data.

根据伦敦证券交易所集团（LSEG）的数据，由合作伙伴赛诺菲集团（SASY.PA）记录的 Dupixent 全球净销售额增长 38%，达到约 60 亿美元，高于 53.4 亿美元的预期。

Quarterly U.S. sales of the high dose version of its eye drug, Eylea, rose 52% to $596 million, driven by higher demand and sales volumes, partly offset by lower prices.

其眼药 Eylea 高剂量版本在美国的季度销售额增长 52%，达到 5.96 亿美元，受需求和销量增加的推动，部分被价格下跌所抵消。

The company said sales of the lower-dose version were hurt by continued competitive pressures and the transition of patients to the 8-mg version.

该公司表示，低剂量版本的销售受到持续竞争压力以及患者向 8 毫克版本过渡的影响。

Regeneron said it fully repaid the Sanofi Development Balance, which represented the outstanding amount due to Sanofi for its funding of prior collaboration development activities.

再生元制药表示，已全额偿还赛诺菲集团开发余额，该款项代表此前合作开发活动中应付给赛诺菲集团的未偿金额。

Marked commercial outperformance may help boost sentiment, and, coupled with the step-up in margins from the Sanofi repayment, should make second half numbers look much better, said RBC Capital Markets analyst Brian Abrahams.

加拿大皇家银行资本市场分析师 Brian Abrahams 表示，显著的商业优异表现可能有助于提振市场情绪，再加上因偿还赛诺菲款项而带来的利润率提升，应会使下半年的财务数据看起来更加亮眼。

Quarterly revenue rose 17% to $4.29 billion, surpassing estimates of $3.82 billion.

季度营收增长 17%，达到 42.9 亿美元，高于 38.2 亿美元的预期。

The Tarrytown, New York-based drugmaker posted a quarterly non-GAAP adjusted profit of $14.29 per share, beating the analyst estimate of $10.26.

这家总部位于纽约塔里敦的制药公司公布季度非 GAAP 调整后每股收益为 14.29 美元，高于分析师预期的 10.26 美元。